Mass cytometry papers in blood cancers from 2020

07-Jan-2021

Marcel Doerflinger

Materials

17 patients

Number of markers

17 markers

Patients with multiple myeloma are more susceptible to infections. Authors conducted mass cytometry research to identify predictive markers for infection. No detection of phenotypic or numerical differences in immune cell populations between patients that did and did not develop infections. Transcriptional profiling of stimulated PBMCs revealed distinct Th2 immune pathway signatures in patients that developed infection.

Successful identification of predictive profiles for infection utilising systems‐level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma

Clinical and Translational Immunology

13-Oct-2020

Slavica Vuckovic

Materials

PB of 4 MGUS 8 NDMM

Number of markers

37 markers

Analysis of CD8+CD57+ terminal effector T cells in the bone marrow and peripheral blood of age-matched controls and patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), and newly diagnosed (ND) MM

Inverse relationship between oligoclonal expanded CD69− TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients

Blood advances

23-Aug-2020

Fathima Zumla Cader

Materials

7 patients Hodgkin disease and 10 patients without malignant disease (but lymphoid hyperplasia).

Number of markers

39 markers

Comparison between Hodgkin lymphoma biopsies and control reactive lymph node/tonsil samples. In Hodgkin lymphoma: expression of T helper 1 (Th1)-polarized Teffs and regulatory T cells (Tregs).

Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment

Blood

21-Aug-2020

Melissa M. Berrien-Elliott,

Materials

1 patient or in vitro cells

Number of markers

37 markers

Study of NK cell therapy in leukemia patients. NKG2A is a dominant, transcriptionally-induced checkpoint important for ML, but not conventional NK cell responses to cancer. The frequency of CD8a+ donor NK cells is negatively associated with AML patient outcomes after ML NK therapy

Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia

Cancer discovery

10-Aug-2020

Fathima Zumla Cader

Materials

56 patients

Number of markers

39 markers

Study of the peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial. CD4+, but not CD8+, TCR diversity significantly increased during therapy, most strikingly in patients who had achieved complete responses. Responders show a newly identified CD3−CD68+CD4+GrB+ subset and activated NK cell subset.

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Nature Medicine

22-July-2020

Gautam Borthakur

Materials

2 patients

Number of markers

Non available

Phase I trial involving sorafenib, plerixafor and G-CSF

Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients

Hematology

21-July-2020

Jithendra Kini Bailur

Materials

36 B cell acute lymphoblastic leukemia, 28 acute myeloid leukemia, 11 healthy donors

Number of markers

37 markers

Combination of mass cytometry, single cell genomics, and functional studies to characterize the BM immune environment in children with B cell acute lymphoblastic leukemia and acute myelogenous leukemia at presentation

Risk-associated alterations in marrow T cells in pediatric leukemia

JCI Insight

22-Jul-2020

Gautam Borthakur

Materials

2 patients analyzed by CyTOF

Number of markers

30 markers

Mass cytometry analysis of sequential samples from two patients demonstrated resistance emerging early on from sub‐clones with persistent Akt and/or ERK signaling

Phase 1 Study of combinatorial sorafenib, G‐CSF , and plerixafor treatment in relapsed/refractory, FLT3‐ITD ‐mutated acute myelogenous leukemia patients

American Journal of Hematology

20-Jul-2020

Edit Kotogány

Materials

2 patients

Number of markers

15 markers

Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative drug candidate on human
patient-derived AML cells showed an increase of CD11b and decrease of CD33+, CD7+, CD206+,
and CD38bright cells followed apoptosis after treatment ex vivo.

Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of
Immature Myeloid Cells Such as Acute Myeloid
Leukemia and Myeloid-Derived Suppressor Cells

International Journal of Molecular Sciences

21-Jul-20

Jithendra Kini Bailur

Materials

64 patients

Number of markers

37 markers

Characterization the bone marrow immune environment in children with B-cell acute lymphoblastic leukemia, and acute myelogenous leukemia at presentation. T cells in leukemia marrow demonstrate evidence of chronic immune activation and exhaustion/dysfunction, , with attrition of naïve T cells and TCF1+ stem-like memory T cells and accumulation of terminally-differentiated effector T cells.

Risk associated alterations in marrow T cells in pediatric leukemia

JCI Insight

30-Jun-20

Zhi-Zhang Yang

Materials

82 follicular lymphoma patients

Number of markers

37 markers

Mass cytometry shows that TIGIT is highly expressed on intratumoral T cells and its expression alters T cell phenotype in Follicular Lymphoma. Increased numbers of TIGIT+ T cells are associated with inferior patient outcomes and poor survival.

TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma

Clinical Cancer Research

05-Jun-20

Srividya Swaminathan

Materials

Lymphoma murine cancer model and human human cells

Number of markers

Mouse 15 markers / human: 32 markers

Systemic reduction in natural killer (NK) cell numbers in SRα-tTA/Tet-O-MYCON mice bearing MYC-driven T-lymphomas. CyTOF provided a rationale for developing NK cell-based therapies to effectively treat MYC-driven lymphomas in the future.

MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies

Nature Communications

26-May-20

Tineke Casneuf

Materials

149 patient samples and 38 control samples

Number of markers

37 markers

Daratumumab’s effects on immune cells in whole blood samples of relapsed/refractory Multiple Myeloma patients from both treatment arms (lenalidomide/dexamethasone or daratumumab plus Rd) at baseline and after 2 months on treatment using mass cytometry. CyTOF showed NK cell reduction with Daratumumab-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep responders to Daratumumab-Rd, with a higher proportion of CD8+ versus CD4+ T cells.

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

Leukemia

15-May-20

Abhishek A. Mangaonkar,

Materials

7 chronic myelomonocytic leukemia (CMML) patients and 3 controls

Number of markers

30 markers

Aggregate IDO1+ dendritic cell populations occur in the chronic myelomonocytic leukemia bone marrow microenvironment, and their presence correlates with disease progression.

Indoleamine 2,3-dioxygenase-1 expressing aggregate bone marrow dendritic cell populations are associated with systemic T-cell compartment changes in chronic myelomonocytic leukemia

bioRXiiv

12-May-20

Tamara Davenne

Materials

14 patients with CLL

Number of markers

28 markers

Mass cytometry finds that deoxyguanosine and forodesine kill SAMHD1-deficient malignant cells in patients with chronic lymphocytic leukemia (CLL). Normal cells and CLL cells from patients without SAMHD1 mutation are unaffected by treatment. CyTOF could distinguish between all populations.

SAMHD1 Limits the Efficacy of Forodesine in
Leukemia by Protecting Cells against the
Cytotoxicity of dGTP

Cell Reports

01-May-20

Manman Denga

Materials

18 AML patients

Number of markers

8 markers

VEGF/VEGFRs correlates with chemotherapy resistance in AML
VEGF/VEGFRs correlates with poor clinical outcome in AML

Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis

Experimental Cell Research

29-Apr-20

Jinheng Wang

Materials

5 Healthy BM versus 10 MM BM

Number of markers

30 markers

Masss cytometry revealed an increase in activated CD4 T, CD8 T, CD8+ natural killer T‐like and NK cells in Multiple Myeloma in Bone Marrow

Identification of the immune checkpoint signature of multiple myeloma using mass cytometry‐based single‐cell analysis

Clinical & Translational Immunology

21-Apr-20

Adam J. Lamble

Materials

Bone marrow and peripheral blood samples from patients with newly diagnosed AML

Number of markers

2 panels: 35, 34

Association between T cell infiltration in the bone marrow microenvironment of newly diagnosed patients with AML and increased overall survival.

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia

PNAS

11-Feb-20

Palash C. Maity

Materials

nonstereotypic CLL samples and analyzed B cells isolated from 5 healthy donors (HDs) as control.

Number of markers

23 markers

Healthy B cell isolates were limited to 3 major phenotypically discrete clusters, CLL samples allocated 14 independent phenotypic clusters. Mutated CLL cells were phenotypically different from unmutated CLL cells and shared only 1 phenotypic cluster.

IGLV3-21*01 is an inherited risk factor for (chronic lymphocytic leukemia) CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling

PNAS

27-Jan-20

Charis E Teh

Materials

M.1S, OPM2, AMO1, U266, KMS-12-BM, or H929 cells

Number of markers

26 markers

Treatment of myeloma cells with dexamethasone or bortezomib and the authors studied the effect of the treatment with mass cytometry. Increased amounts of phosphorylated cAMP and the pro-survival protein MCL-1 were defining features of cells surviving drug treatment. CyTOF analysis of patient bone marrow cells identified myeloma cells and their key cell survival features.

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Cell Death & Differentiation

09-Jan-20

Mikael Roussel

Materials

22 tissues samples were analyzed, from 16 lymphoma patients and 6 control samples

Number of markers

35 markers

Mass cytometry proves that CD163, CD68, S100A9, CCR2, CD36, Slan, and CD32 should be measured to effectively characterize lymphoma-specific tumor macrophages

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas

Cancer Immunology, Immunotherapy

19-Dec-19

Aoki, T et al.

Materials

22 Hodgkin lymphoma tissue specimens and 5 reactive lymph nodes, validation with 166 patients

Number of markers

Not accessible

Identification of novel Hodgkin lymphoma: mass cytometry highlited an association with a subset of LAG3+ T cells

Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma

Cancer Discovery

29-Nov-2020

Astrid Tschan-Plessl

Materials

10 patients

Number of markers

36 markers

Investigate the feasibility and safety of haploidentical natural killer (NK) cell infusions as consolidation immunotherapy. Multiparametric mass cytometry analysis demonstrated an altered surface receptor repertoire of expanded NK cells with increased degranulation and cytokine production activities but diminished expression of perforin.

Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma

Cytotherapy

2-July-2020

Leandro Venturutti

Materials

Mice

Number of markers

Intra and extracellular marker

TBL1XR1 mutation skews the humoral immune response toward producing memory B cells.

TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate

Cell

23-July-2020

Kim A Reiss

Materials

15 patients

Number of markers

37 markers

Administration of TGF-β inhibitor with stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC). Study of the blood. Treatment with galunisertib was associated with a decrease in the frequency of activated T regulatory cells in the blood. Non-progressors also had increased CD8+PD-1+TIGIT+ T cells in the blood after treatment.

A Pilot Study of Galunisertib Plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Molecular Cancer Therapeutics

14-Sept-2020

William E. Pierceall1

Materials

6 patients

Number of markers

39 markers

Study of combination treatment f daratumumab to pomalidomide and lowdose dexamethasone. Immunophenotypic changes were analyzed in peripheral blood.

Immunomodulation in Pomalidomide, Dexamethasone,
and Daratumumab-Treated Patients with Relapsed/
Refractory Multiple Myeloma

Clinical Cancer Research

​

​

Materials

​

Number of markers

​

​

​

​